SCHEMBL6890781

SCHEMBL6890781

NC(=O)c1nnc2ccccc2c1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.69
MAP2K3 P46734 1/20 0.69
MAP2K6 P52564 1/20 0.69
BTK Q06187 1/20 0.69
MAP3K19 Q56UN5 1/20 0.69
NEK10 Q6ZWH5 1/20 0.69
GPR3 P46089 1/20 0.46
LRRK2 Q5S007 7/20 0.42
ELANE P08246 1/20 0.38
DYRK1A Q13627 1/20 0.37
ALDH1A1 P00352 1/20 0.37
ATM Q13315 1/20 0.37
DHODH Q02127 1/20 0.37
PDE10A Q9Y233 1/20 0.37
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
ILK Q13418 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
THRB P10828 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7706331 0.83 LCK (0.51) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL31371878 0.83 LCK (0.51) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL9525498 0.81 LCK (0.50) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL14061350 0.81 BTK (1.00) LCKMAP2K3MAP2K6BTKMAP3K19
Aminomethylamide SCHEMBL27390143 0.80 LCK (0.50) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL30471260 0.80 LCK (0.67) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL14058931 0.80 LCK (0.67) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL1332157 0.78 MAP2K3 (0.50) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL1123696 0.77 KDM4E (0.47) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL15756098 0.76 LCK (0.61) LCKMAP2K3MAP2K6BTKMAP3K19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9884828-B2 Substituted cinnolines as inhibitors of LRRK2 kinase activity IMAGO PHARMACEUTICALS, INC. (US) 2018-02-06 US disclosed
US-9884828-B2 Substituted cinnolines as inhibitors of LRRK2 kinase activity IMAGO PHARMACEUTICALS, INC. (US) 2018-02-06 US disclosed
US-20150284337-A1 INHIBITORS OF LRRK2 KINASE ACTIVITY ELAN PHARMACEUTICALS, INC. (US) 2015-10-08 US disclosed
US-6693114-B2 N-(4-CHLOROBENZYL)-6-(3-HYDROXY-1-PROPYNYL)-1-7-DIMETHYL-4-OXO-1,4 -DIHYDRO(1,8) NAPHTHYRIDINE-3-CARBOXAMIDE FOR EXAMPLE; INHIBITING VIRAL DNA POLYMERASE; TREATING HERPES VIRUS INFECTIONS PHARMACIA & UPJOHN COMPANY 2004-02-17 US disclosed
EP-1265873-B1 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS UPJOHN CO (US) 2003-10-15 EP disclosed
US-6624160-B2 Especially infections of herpes simplex virus type 1, 2, 6, 7, or 8, varicella zoster virus, human cytomegalovirus or epstein-Barr virus; enzyme inhibitors of virus DNA polymerase PHARMACIA & UPJOHN CO. 2003-09-23 US disclosed
CN-1418214-A 4-Hydroxy-1, 8-Naphthyridine-3-carboxamides as antiviral agents UPJOHN CO (US) 2003-05-14 CN disclosed
CN-1406228-A 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents UPJOHN CO (US) 2003-03-26 CN disclosed
CN-1398258-A 4-Hydroxycinnoline-3-carboxamide compounds as antiviral agents UPJOHN CO (US) 2003-02-19 CN disclosed
CN-1398258-A 4-Hydroxycinnoline-3-carboxamide compounds as antiviral agents UPJOHN CO (US) 2003-02-19 CN disclosed
US-20020042397-A1 4-hydroxycinnoline-3-carboxyamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-04-11 US disclosed
US-20020019413-A1 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-02-14 US disclosed
US-20020007066-A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-01-17 US disclosed
WO-2001081318-A1 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-11-01 WO disclosed
WO-2001074816-A1 4-OXO-1,4-DIHYDRO[1,8]NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-10-11 WO disclosed
WO-2001070706-A2 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-09-27 WO disclosed
WO-2001070742-A1 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-09-27 WO disclosed
EP-0277791-B1 CINNOLINE-CARBOXAMIDES AND PROCESS FOR THEIR PREPARATION FARMITALIA CARLO ERBA S.r.l. (IT) 1993-06-02 EP disclosed
US-4826837-A IMMUNOMODULATORS FARMITALIA CARLO ERBA S.R.L. (IT) 1989-05-02 US disclosed
EP-0277791-A2 Cinnoline-carboxamides and process for their preparation FARMITALIA CARLO ERBA S.r.l. (IT) 1988-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042397-A1 4-hydroxycinnoline-3-carboxyamides as antiviral agents HAVCR2, ZC3HAV1, HCFC1 LCK 4523/4885MAP2K3 4826/4885MAP2K6 4859/4885
US-20150284337-A1 INHIBITORS OF LRRK2 KINASE ACTIVITY LRRK2, PARK7, PINK1 LCK 472/4885MAP2K3 306/4885MAP2K6 303/4885
US-20020019413-A1 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents IRF3, ZC3HAV1, EIF2AK2 LCK 2787/4885MAP2K3 3788/4885MAP2K6 4360/4885
US-20020007066-A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents CNR1, HAVCR2, NR1H4 LCK 4569/4885MAP2K3 3838/4885MAP2K6 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.